

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled)

Claim 2 (currently amended): The method according to claim 12 40, wherein the pulmonary hypertension is selected from primary pulmonary hypertension or secondary pulmonary hypertension.

Claim 3 (canceled)

Claim 4 (cancelled):

Claim 5 (currently amended): The method according to claim 12 40 wherein the pulmonary hypertension is not caused or accompanied by pulmonary fibrosis.

Claim 6 (canceled)

Claim 7 (currently amended): The method according to claim 12 40 wherein N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine is in the form of the monomethanesulfonate salt.

Claim 8 (canceled)


Claim 9 (canceled)

Claim 10 (cancelled)

Claim 11 (currently amended): The method according to claim 12 40 wherein the daily dose is administered for a period exceeding 3 months.

Claim 12 (new): A method of treating a human patient suffering from pulmonary hypertension which comprises providing the patient with a curative treatment by administering to the patient a daily dose of 100 to 1000 mg of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-

methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine



(I)

or a pharmaceutically acceptable salt thereof.